Kura Oncology reported $2.1 million in net product revenue from KOMZIFTI for the period between November 21, 2025, and December 31, 2025.
The company is focused on advancing precision medicines for cancer treatment, with a deep pipeline of transformative therapies.
Key achievements include FDA approval of KOMZIFTI for adult patients with relapsed or refractory acute myeloid leukemia (AML) and inclusion in NCCN Guidelines.
Landmark FDA Approval
KOMZIFTI, the first once-daily oral menin inhibitor for R/R NPM1-mutated AML, received FDA approval in November 2025.
Financial Performance
$2.1 million KOMZIFTI net product revenue reported in a five-week period in December 2025.
Pipeline Advancements
Anticipated milestones include expanding KOMZIFTI use, presenting data on combination therapies, and advancing Phase 3 trials.
- Kura Oncology shows promising growth potential with initial revenue generation from KOMZIFTI and strategic plans for pipeline expansion.
- The FDA approval and NCCN inclusion underscore the company's commitment to innovative cancer treatments and market presence.
With a successful commercial launch of KOMZIFTI and ongoing development of combination therapies, Kura Oncology's outlook for 2026 is optimistic and focused on delivering impactful treatments for cancer patients.